With a flurry of recent activity, 17 trial sites are now open for enrollment. We are especially excited to share that our first international sites in Canada and Australia have launched. Sites are also expected to launch soon in Europe and Israel.
SRPT press release – golodirsen NDA acceptance 02 14 19
We are excited about the UT Southwestern Wellstone Symposium on March 30! Don’t forget to RSVP by March 1. We’ll see you there!
Thursday February 28th at 4pm Dr. Eric Olson is giving a talk at the President’s Lecture at UT Southwestern (South Campus Gooch Auditorium) and will be highlighting the DMD project. Steve Gray, PhD is also speaking about gene therapy. The lecture is open to the general public.
We are excited that our industry partner, NS Pharma, has applied for accelertated approval for it’s exon 53 skipping therapy, viltolarsen. We applaud the dedication to the Duchenne community by NS Pharma and look forward to continued success. NS Pharma Community Letter
We’re pleased to share this letter and news from our partner Santhera about their plans for 2019! For more than 10 years, Santhera has been working on treatments for DMD, and 2019 will bring more clinical trials and research for our community. We’re proud to have Santhera as a partner and look forward to seeing […]
Highlights from day three at the World Muscle Society meeting in Mendoza, Argentina, provided by CureDuchnne’s scientist, Dr. Mike Kelly. Mallinckrodt Pharmaceuticals Mallinckrodt provided an update on their Phase 2 multicenter, double-blind, placebo-controlled study, assessing the safety and efficacy of MNK-1411 in Duchenne patients. MNK-1411 is an injectable synthetic 24-amino acid peptide analogue of adrenocorticotrophic […]
Highlights from day two at the World Muscle Society meeting in Mendoza, Argentina, provided by CureDuchnne’s scientist, Dr. Mike Kelly. Sarepta’s Gene Therapy Program: Sarepta provided a much-anticipated update on their dystrophin mini gene clinical study. The latest data release reinforced the positive news reported earlier for the first three patients. Today’s data — for […]
Highlights from the first day at the World Muscle Society meeting in Mendoza, Argentina, provided by CureDuchnne’s scientist, Dr. Mike Kelly. Carrier-mothers: It’s recognized that Duchenne and Becker muscular dystrophy carrier-mothers are at high risk for developing various dystrophic complications. Recent studies suggest that the incidence of cardiac and non-cardiac manifestations occurs earlier (and with […]
Dear Friends, Today, our partner Dr. Eric Olson and his team at Exonics, a company CureDuchenne helped form, published data in the online journal, Science that shows an increase in dystrophin restoration of 92% in the heart of the canine’s. As the only Duchenne nonprofit organization to support Dr. Eric Olson’s work through Exonics, and […]